The legacy of Viagra and its effect on the pharmaceutical sector presents a complex question regarding its continued attractiveness as an investment. Initially a phenomenal success, generating vast revenues, generic competition has considerably eroded profit margins . While leading pharmaceutical firms maintain patents on related therapies and inve

The trajectory of companies tied to blockbuster drugs like Viagra presents a nuanced investment landscape . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial wealth , the expiry in key markets has introduced significant risk . Investors are now grappling with the impact of generic competition ,